Cure Alveolar Soft Part Sarcoma International (iCureASPS)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747319/
from (5):
A global rate of 21% patients received TBP for more than 6 weeks and 7% of the intention to treat population had a ≥30% tumor shrinkage versus baseline after TBP [55]. Moreover, a subgroup of patients treated with nivolumab in the CheckMate 025 trial achieved a benefit from TBP, showing a tumor reduction after the first PD [56].
so either the scanning was wrong or there was a response after the initial true progression.
we are using data from RCC trials as this is the closest cancer by typical clinical history and by the morphology to ASPS

Olga
Great article .
I couldn’t agree with you more that a look see at the 3rd dimension , is truly an important clue to assess the true response to these ICIs success and or failures .

Also to utilize all means available( ctdna circulating tumor DNA, biomarkers and follow up scans ) to check pseudo verses progressive disease , when taking a patient off ICIs.

These earlier statistics certainly gave us the beginning picture to begin to unravel a complex set of events.